Share Twitter LinkedIn Facebook Email Roy S. Herbst, MD, PhD, shares his thoughts on whether Keynote 189 impacted view of PDL-1 expression and patient selection. Advertisement
ASCO 2025: Lung Cancer Immunotherapy Breakthroughs from the Immuno-Oncology Symposium Lung Cancer Treatment 4 Mins Read